AnaptysBio Q3 net loss $33.5M ($1.18/sh); cash $590.5M; alopecia areata data Q1 2023

ANAPTYSBIO, INC

2022-Q3 EPS reported -$3.64 revenue$3,479,000

Net loss $33.5M (Q3 2022) vs $6.7M (Q3 2021); loss/share $1.18 vs $0.24.
Cash & investments $590.5M as of Sep 30, 2022, down $24.7M from Dec 31, 2021.
Collaboration revenue fell to $1.3M (Q3 2022) from $20.9M (Q3 2021) on no GSK milestones.
Rosnilimab Phase 2 alopecia areata top-line data expected Q1 2023; ANB032 IND Q4 2022.
Zejula royalty sale to DRI for up to $45M ($35M upfront); GSK earned $5M milestone for cobolimab Phase 3.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ANAPTYSBIO, INC reported financial results for three and nine months ended September 30, 2022.

Period: three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-22-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.